Patient FAQ

# Answers to your questions

Practical answers about our investigational therapy, clinical trials and what participation involves. Your care team is always your best source of advice.

Ask a question → Clinical trials

The therapy

## About the investigational therapy

###

Zent-001 is an oral, once-daily kinase inhibitor taken at home. It targets WEE1 kinase, a key regulator of cell-cycle progression that cancer cells depend on to survive and divide.

###

No. It is a targeted therapy designed to interrupt a specific mechanism in cancer cells. It is being developed as a non-chemotherapy option with a more convenient, oral administration.

###

No. Zent-001 is investigational and has not been approved by the FDA, EMA or any health authority. It is being studied in clinical trials to evaluate its safety and effectiveness.

###

As with any medicine, there are potential side effects. Your study team will explain the known risks and monitor you closely throughout participation.

Trials & participation

## About clinical trials

###

Trials use a companion diagnostic to identify biomarker-positive patients whose tumors carry Cyclin E1 amplification — pairing each person with the therapy most relevant to their disease biology.

###

Contact our patient information team or speak with your oncologist. We can help identify a participating site and connect you with the trial team to confirm eligibility.

###

A small sample of your tumor tissue is tested for Cyclin E1 amplification. The result helps the study team determine whether the trial is a potential match for you.

###

Yes. Participation is entirely voluntary. You may leave a trial at any time, for any reason, without affecting your other medical care.

###

Trials operate at 40+ sites worldwide, and our team will help you find the nearest participating center. Scheduling and travel support are available where appropriate.

?

> Still have a question? Our patient information team is here to help — no question is too small.

Contact patient support →